Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products
OTTAWA, Nov. 01, 2018 (GLOBE NEWSWIRE) — Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.
The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.
“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,” stated Richard Giguere, CEO of Tetra Natural Health.
“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,” stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that addressactivities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, withoutlimitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements aregenerally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statementsare subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may causethe actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could causeactual results or events to differ materially from current expectations include, among other things, without limitation, the inability ofthe Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated andunanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability toobtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertaintiesrelated to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions,the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s publicdisclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify importantfactors that could cause actual results or events to differ materially from those described in forward-looking statements, there may beother factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance onforward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that suchdocumentation will be signed. The forward-looking statements included in this news release are made as of the date of this newsrelease and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect newinformation, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert BechardExecutive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]
Stephanie Engel
416-425-9143 ext. 209
[email protected]
Source: Tetra Bio-Pharma Inc